BVI Company News

China Unistone Acquisition Corp. on November 6 announced the date of its special meeting of stockholders to be November 24. The first date announced previously was November 21, 2006. During this special meeting the stockholders will be entitled to vote on three proposals. The first proposal is the approval the acquisition of two companies – Beijing e-Channels Century Technology Co., Ltd. and Beijing Sihitech Co., Ltd. with its subsidiaries. The second proposal is the approval of the China Unistone 2006 Performance Equity Plan. The third one is the merger of China Unistone into its wholly owned subsidiary registered in the British Virgin Islands, with the purpose of re-domestication of the corporation.

China Unistone Acquisition Corp. is a public company organized for the purpose of acquiring businesses in China. Pursuant to the company’s certificate of incorporation, each China Unistone stockholder who holds shares of common stock issued in China Unistone’s initial public offering has the right to vote against the acquisition proposal and demand that, if the acquisition is consummated, China Unistone convert such stockholder’s shares into cash.

If the holders of 20% common stock shares vote against the acquisition proposal and properly exercise their conversion rights, China Unistone will not finish the business combination.

CDoor Corp. made an announcement that on November 2 it entered into a letter of intent to acquire 100% of the issued and outstanding shares of BVI-registered Wanxin Bio-Technology Limited (Wanxin), in exchange for 34,000,000 post forward stock-split shares of CDoor.

CDoor intends to forward split its issued and outstanding shares on a basis of 20 new shares for each one old share which would result in the current outstanding shares of 3,025,000 becoming 60,500,000 shares.

Wanxin is the sole shareholder or the owner of the right to acquire all of the issued and outstanding shares in the capital of Hong Kong company Manhing Enterprises Limited; Manhing Enterprises, in its turn, is the registered owner of 82% of the capital of Shanghai Wanxing Bio-pharmaceuticals Co., Ltd. (Shanghai Wanxing). This Chinese company based in Shanghai is a leading country’s developer of genetically engineered recombinant protein drugs and vaccines.

After the proposed acquisition of Wanxin there would be a total of 94,500,000 shares outstanding subject to the possible cancellation of some common shares held by the controlling shareholder, Mr. Ka Yu.

Another announcement made by CDoor Corp. concerned the fact of acquisition of 2,000,000 shares of the company held by Messrs. Lavi Krasney and Asher Zwebner and representing approximately 66% of the issued and outstanding shares of CDoor. The purchaser of the shares, Mr. Ka Yu, by this transaction has become the controlling shareholder of the company.